NCT00034203已完成2 期

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

XOMA (US) LLC99 个研究点分布在 1 个国家开始时间: 2002年4月最近更新: 2005年6月24日

研究概览

简要总结

The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.

研究设计

研究类型: Interventional
分配方式: Randomized
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 18 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

XOMA (US) LLC

申办方类型

Industry

研究点 (99)

Loading locations...

相似试验

已完成

1 期

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic ArthritisPsoriatic Arthritis

NCT00051662XOMA (US) LLC45

已完成

1 期

Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV InfectionHIV Infections

NCT02591420National Institute of Allergy and Infectious Diseases (NIAID)24

已完成

1 期

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult ParticipantsHIV Infections

NCT03735849National Institute of Allergy and Infectious Diseases (NIAID)28

撤回

2 期

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19COVID-19

NCT04770467Brii Biosciences, Inc.

已完成

2 期

Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV InfectionHIV Infections

NCT02664415National Institute of Allergy and Infectious Diseases (NIAID)23